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Background: Pharmacovigilance aims to uncover and understand harmful side-effects of drugs, termed adverse
events (AEs). Although the current process of pharmacovigilance is very systematic, the increasing amount of
information available in specialized health-related websites as well as the exponential growth in medical literature
presents a unique opportunity to supplement traditional adverse event gathering mechanisms with new-age ones.
Method: We present a semi-automated pipeline to extract associations between drugs and side effects from
traditional structured adverse event databases, enhanced by potential drug-adverse event pairs mined from
user-comments from health-related websites and MEDLINE abstracts. The pipeline was tested using a set of
12 drugs representative of two previous studies of adverse event extraction from health-related websites and
MEDLINE abstracts.
Results: Testing the pipeline shows that mining non-traditional sources helps substantiate the adverse event
databases. The non-traditional sources not only contain the known AEs, but also suggest some unreported AEs for
drugs which can then be analyzed further.
Conclusion: A semi-automated pipeline to extract the AE pairs from adverse event databases as well as potential
AE pairs from non-traditional sources such as text from MEDLINE abstracts and user-comments from health-related
websites is presented.
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BCPNNBackground
With the large and growing set of medication drugs, it is
very essential to assess the effects of medication on the pa-
tient population at large via information gathering and
analysis. Since there are practical limits on the degree to
which safety of drugs can be established prior to marketing
approval, it is only through such mechanisms that can we
understand the safety and harmful side effects of adminis-
tered drugs. Typically, pre-marketing safety studies such as
clinical trials are spread over a short duration and re-
stricted to a small and mostly homogeneous study popula-
tion. Furthermore, side effects of drugs are often revealed
after the drug is out in the market being administered to a* Correspondence: adityar.rao@tcs.com
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distribution, and reproduction in any mediumpopulation, sometimes concomitantly with other drugs.
Thus, it is critically important to constantly monitor the
safety of drugs that have been launched in the market. To
provide an objective basis for assessing the safety of mar-
keted drugs, regulatory agencies have in place a post-
marketing surveillance mechanism called Pharmacovigi-
lance (PV) [1]. As per World Health Organization (WHO),
PV is defined as “the science and activities relating to the
detection, assessment, understanding, and prevention of
adverse effects or any other drug-related problems” [2,3].
PV is required for systematically identifying causal asso-
ciations between drugs and side-effects and taking correct-
ive actions, both for new drugs being launched, as well as
for drugs already in use. It is based on the collection of
spontaneously reported Adverse Event (AE) reports. Re-
port initiation by health professionals and consumers is
generally voluntary. However, pharmaceutical companiesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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cascade these to various regulatory authorities [3,4]. The
Adverse Event Reporting System database maintained by
the US Food and Drug Administration (FDA), formerly
called the Adverse Event Reporting System (AERS) and
now referred to as the FDA Adverse Event Reporting Sys-
tem (FAERS) [5], collates all such reports and makes them
available to the public at large [6]. Adverse events can be
reported by pharmaceutical companies, health-care pro-
fessionals as well as the general public. Such Spontaneous
Reporting Systems (SRS) have certain limitations such as
the potential AE reports being incomplete or inaccurate as
a result of voluntary reporting; cases of biased reporting
or under-reporting; or “Patient Reporter Event and Drug”
(PRED) requirements for submission, geographic market-
ing and population varying for different drugs [1].
Mining of probable AE pairs in the FDA SRS has also
been well studied [6]. Various studies have also looked at
mining potential AEs from unstructured text sources
such as Electronic Health Records (EHR), health-related
websites and the MEDLINE database [7], serving as a
complement to the SRS systems. Some studies have been
done taking into account electronic health record data-
bases to analyze drug safety such as EU-ADR [8,9],
OMOP [10], Mini-Sentinel [11] as well as databases such
as MEDLINE and Drugbank [12]. These studies show
that combining the same types of data from multiple
sources could help in better detection of potential AEs.
Of course, sources such as EHR are not easily accessible
due to privacy concerns. Another study was done involv-
ing the knowledge collected from publicly available
drug-related information sources, UMLS [13], FAERS
and SemMed [14], focusing on the ‘drug-indication’ as-
sociation [15]. A key aspect when detecting potential
AEs or extracting facts from unstructured text is to ver-
ify the results manually. Other studies have focused on
using machine learning-based systems for the identifica-
tion and extraction of potential AE pairs from MED-
LINE case reports and generation relevant corpora
[16,17]. van Mulligen et al. [18] describe the creation of
a database which contains associations between drugs,
disorders and targets mined from MEDLINE abstracts.
These associations at the sentence-level in texts were
further refined and corrected using human annotators.
The motivation for using unstructured text from
health-related websites to extract AE associations are a
consequence of the recent trend of people tending to
blog about their personal experiences more frequently
than reporting them to physicians. Health-related web-
sites allow people to discuss their medical conditions
with one another. A system of informal support in terms
of forums facilitates online discussions among people ad-
ministered the same/similar drug. Patients and the general
public write about treatment they are undergoing, as wellas respond to queries on treatment, side effects and re-
lated issues [9]. Such blogs also serve as indicators to the
usage of drugs which might not be strictly in accordance
with the recommended practices. Monitoring the conver-
sations on these websites can alert pharmaceutical com-
panies and regulatory bodies across the world to potential
AE. A study was conducted by annotating 3600 comments
from the health-related website DailyStrength [19,20]. This
study showed that though user-comments pose a signifi-
cant Natural Language Processing (NLP) challenge, they
do contain useful information which could be prove bene-
ficial on further exploration.
The studies of Wang et al. [1] and Leaman et al. [20]
are significant for mining potential AEs from unstruc-
tured text sources. Wang et al. focused on demonstrat-
ing the feasibility of using narrative text in EHRs and
association statistics for PV to detect novel AEs using
NLP. They used the MedLEE (Medical Language Extrac-
tion and Encoding) system for extracting and encoding
information in clinical narratives such as the discharge
summaries of inpatients. Their study was built on their
previous work by adapting a combination of NLP and
statistical methods to acquire potential AE associations.
A chi-square test adjusted with volume was used on the
co-occurring AE pairs to determine possible signals from
them [1]. This work provided a possible method to es-
tablish safety profiles from unstructured patient data for
a drug during its market life. However, it does not lever-
age the large amount of data available in health-related
websites.
Leaman et al. [20] studied the validity of identifying
associations between drugs and AEs reported by patients
in the user comments of health-related websites. They
implemented an automatic web crawler in their study
that efficiently gathered user comments about specific
drugs from the DailyStrength website. A dictionary com-
piled from four different sources viz COSTART vocabu-
lary [21], SIDER side effects [22], the Canadian Drug
Adverse Reaction Database MedEffect [23] and UMLS
concept identifiers [13] - was used to extract the adverse
drug reactions from these user comments. This work
concluded that while mining user comments does pose
significant challenges, these comments contain informa-
tion that could prove to be useful in PV. However, the
study does not include mining MEDLINE abstracts, as
also using AE pairs from traditional SRS databases.
There is a need for a pipeline that can integrate data
from traditional SRS databases such as the FAERS, user-
comments from health-related websites as well as MED-
LINE abstracts to detect potential AEs and provide
biological context to these potential AEs. These potential
AE pairs should then be compared with those listed in
the label information of the drugs. Finally, statistical
techniques will be used to determine the significant AE
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that can handle these requirements.Methods
The following steps were carried out:
1. Creating the complete pipeline.
2. Running the pipeline on the sources of data like the
MEDLINE abstracts and the user comments from
health-websites, respectively. As a pre-processing
step, this involved obtaining the drug-AE pairs from
each of the three sources. For MEDLINE abstracts
and user-comments, these pairs are obtained using
the Association Map module of PV-TPX. For the
FAERS database, the drug pairs were obtained from
the FDA datasets.
3. Running the BCPNN algorithm on the drug-AE
pairs from individual sources.
4. Comparative analysis of the results from the
BCPNN results in order to identify the potential
adverse events for the drugs.TPX framework
We have previously developed TCS Pubmed eXplorer
(TPX) [24], a web-based tool that supports concept-
assisted search and navigation based on PubMed as the
underlying search engine, to search the MEDLINE data-
base. Although the focus of the TPX pipeline is better
search of MEDLINE using PubMed, certain components
of the TPX pipeline are generic and can be re-used in
many biomedical tasks. We have taken relevant compo-
nents of TPX for the semi-automated pipeline for AE
event detection. In addition, we have developed new mod-
ules for tasks. TPX has 16 concept types, of these the drug,
disease and symptom dictionaries were used in this study.
Additionally, the annotation server was re-used with major
modifications. A modified version of the TPX framework,
hereon referred to as PV-TPX, was used in this study.Named-entity-recognition
One of the most significant tasks was the identification
of drug and adverse event mentions in text from both
MEDLINE as well as health-related websites using
Named-Entity-Recognition (NER). The NER module of
PV-TPX is based on that of TPX and uses dictionary-
based NER techniques for identifying various biological
entities in text. The PV-TPX NER module is part of the
Annotation server that receives the unstructured textual
content and performs a wide range of text-mining tasks.
It was implemented in Java and used as a REST/SOAP
based Web Service [25,26]. The following components
of the NER module were used for processing the text: Part-Of-Speech (POS) Tagger: PV-TPX uses the Java
implementation of the open source MedPost POS
tagger [27] from NCBI, which is an HMM based
POS tagger for parts-of-speech tagging in medical
text.
 Stemmer and Tokenizer: PV-TPX uses the Porter
stemmer algorithm for stemming [28]. An in-house
implementation of tokenizer and sentence splitter
is used for tokenization and sentence splitting
respectively.
 Acronym Handler: PV-TPX also identifies local
abbreviations by keeping track of such abbreviation
definitions. The expansion of the abbreviations is
usually specified in the article abstract, while the
abbreviated form is used in the article title. Hence
the abstract is tagged before the title and all the local
abbreviations detected in the abstract were extended
to the title tagging.
Dictionary compilation
An inherent task for accomplishing NER was building
the dictionaries to be used in the pipeline. While TPX
uses dictionaries for various biological entities such as
genes, proteins, diseases and drugs, none of them could
be used as-is for this study. Instead, a drug dictionary
and an event dictionary consisting of disease and symp-
tom terms for identifying AEs were built as follows:
1. A drug dictionary is based on the TPX drug dictionary
but enhanced with synonym/variants/brand names.
The additional synonyms or variants for each of these
that were compiled from sources such as MeSH [29].
Although not a formal input source, Wikipedia [30]
data was used to cross-check some of the brand
names as it proved to have significant brand names
mentioned.
2. An event dictionary that consists of disease and
symptom terms for identifying AEs. The event
dictionary is primarily derived by merging TPX
disease dictionary and TPX symptom dictionary [24].
Further, MedDRA [31] was used as an important
source for enhancing the event dictionary since
medication errors reported to FAERS are coded to
terms in the MedDRA terminology. Hence, the
MedDRA Preferred Term (PT) and Low Level Term
(LLT) were also added to the event dictionary. To
reconcile disparate mentions of named entities,
normalization was done on the event dictionary as
follows. For an exact match of the MedDRA term
with the dictionary term, all the synonyms of that
MedDRA PT were added as synonyms to the
dictionary term. For MedDRA terms that do not
have an exact match in the dictionary, the terms
were added as separate entries in the dictionary.
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pattern matching was involved. For instance,
MedDRA terms such as ‘abdominal discomfort’,
‘abnormal dreams’ and ‘acute psychosis’ that did not
have an exact match in the dictionary were added to
it as separate entries.
Entity association module
TPX has a pairwise concept association module incorpo-
rated. The Concept association module reads the entity
annotations for the entire MEDLINE and then computes
pairwise associations between the biological entities.
Thus, these associations are pre-computed and ranked
according to their relevance to the whole of the tagged
MEDLINE corpus. Additionally, the associations are
scored based on co-occurrence within the abstracts. The
scoring method is as follows: For an entity e, let A(e) =
{a1, …., ak} denote the set of abstracts e is mentioned.
Let t1,…, tm denote the set of all entities other than e
mentioned in abstracts belonging to A(e). Let A denote
the set of all abstracts. For an entity ti, let N(ti, A) denote
the total number of occurrence of ti in the abstracts in
A. Similarly let N(ti, A(e)) denote the corresponding
number of occurrence of ti in the abstract collection A
(e). The association score P(ti|e) denotes the probability
that ti is relevant given the entity e, is estimated using
the standard tf-idf score as follows:
P tijeð Þ ¼ B tijeð ÞXm
j¼1B tj eÞj

where B tijeð Þ ¼ N ti;A eð Þð Þ log N þ 1N ti; Að Þ
 
where N is the sum total of the frequency of all the
entities in the abstract collection A.
In PV-TPX, the pairwise associations between the
identified entities were calculated using a PV-TPX spe-
cific pairwise entity association map. These pairwise as-
sociations are computed for the MEDLINE corpus as
described above, where each abstract accounts for one
document. However, each individual user comment and
its responses from the health-related websites is consid-
ered as one document while computing the pairwise as-
sociations for this corpus. The resultant set for each
corpus contains the drug-disease and drug-symptom
pairs which were then processed to identify the potential
AE pairs.
BCPNN algorithm
The statistical BCPNN algorithm is used as the means
for signal detection in the pipeline. It uses a neural net-
work architecture to measure dependencies between en-
tities in a dataset of AE pairs. BCPNN can be used todetect unexpected patterns in input data and to examine
how such patterns vary over time [32]. It uses a dispro-
portionality measure known as Information Component
(IC). In BCPNN, node activations represent probability
or confidence in the presence of input features, and syn-
aptic weights are based on estimated correlations and
the spread of activation corresponds to calculating pos-
terior probabilities [33]. The variance values are relevant
when the data is varying and not static.
The BCPNN algorithm has been implemented in Java
for this pipeline, which takes as input, a matrix of the
drug-AE associations and their frequency of occurrence
in that particular source. The output from this is an IC
variance value for each drug-AE pair, which is analyzed
manually to obtain the potential drug-adverse event
pairs. After the identification of drug and symptom or
disease pairs from each source, this data arranged in a
matrix form, which is the required input format for run-
ning the BCPNN algorithm. This implementation pro-
vides the ‘variance’ values for the IC for each of the AE
pairs. The IC value in each source is based on the total
number of documents in the set with drug X (Cx); the
total number of documents with AE entity Y (Cy); the
number of documents with the specific AE combination
(Cxy); and the total number of documents in that source.
A variation in the data may cause the IC to either in-
crease or decrease. The standard deviation for each IC
provides a measure of the robustness of the value. Large
values of Cx, Cy and Cxy indicate smaller confidence
intervals.
The IC is thus a measure of the strength of the de-
pendency between a drug and an AE [33]. A positive IC
value indicates that a particular AE combination is re-
ported to the database more often than expected from
the rest of the reports in the database. An IC value of
zero indicates that there is no quantitative dependency
between the AE combinations while a negative IC value
indicates that the combination is reported to the data-
base less frequently than statistically expected. The
higher value of the IC, the more the combination stands
out from the background. If the IC value increases over
time and the value is positive, the positive quantitative
association between the drug and the adverse e is likely
to be high.
Data acquisition
Data acquisition, which involved identifying the struc-
tured and unstructured sources of data for these drugs
and collecting the data to be mined from them. Data ac-
quisition from unstructured sources was done using the
PV-TPX pipeline, which in turn involved processing the
data from the different sources to identify entities and
finding the associations amongst these entities. The drug
and event dictionaries were used to identify entities.
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The FAERS database was used as the source of struc-
tured data. The FDA releases Adverse Event Reaction in-
formation on a quarterly basis. The drug, reaction,
indication, outcomes, report sources, therapy and demo-
graphics files have been extracted from each quarter’s
archive and loaded into a relational database. The drug-
AE pairs have been obtained from the drug and reaction
tables based on the Individual Safety Report (ISR) field.
Duplicates were eliminated and unique drug-AE pairs
were obtained for each ISR and case-id. Demographics
information such as ISR, case-id, initial or follow-up
code, age, gender, event date and reporting date were
used for selecting unique records. The initial and follow-
up cases were considered as two different instances of
the association.
Before performing association mining on the data,
normalization was done by comparing each of the drug
and AE entities with the baseline dictionary and using
the generic names or common synonyms for them. If
the reaction or AE entity matched with the dictionary
term, then the dictionary entry was used, otherwise the
reaction entity was used as-is for further processing.
The FAERS files from the first quarter of 2008 to the first
quarter of 2012 were obtained from the FDA website for
this study. Therefore, the data was divided into three cat-
egories to observe the variance. The three categories are:
1. The complete set of data for each data source:
FAERS data for all quarters from Q1 2008 to Q1
2012, all the blogs from the three health-related
websites and all the abstracts from MEDLINE.
2. Data between January 01, 2008 and December 31,
2009: The FAERS drug-PT pairs with the FDA
reported date within the given date range, the blogs
from PatientsLikeMe and Mediguard with dates in
the given range, the complete Dailystrength blogs
and AE pairs from MEDLINE abstracts that have
publication dates in the given range.
3. Data between January 01, 2010 and March 31, 2012:
Similar to the above set.
Unstructured-data acquisition
The user comments from health-related websites “Patient-
sLikeMe” [34], DailyStrength [19] and MediGuard [35]
were used as sources of unstructured text. These blogs
were crawled using Web-Harvest, an open-source web
data extraction tool [36]. The user comments, reviews and
replies were retrieved from these websites for the pre-
defined set of drugs. These blogs also provide some user
information such as the user-name, age, gender and
demographics. However, since the study does not aim at
categorizing the results based on these parameters, none
of this additional information was used for processing.The other source of unstructured text is the MEDLINE
database, which has over 23 million abstracts [7] Figure 1.
Testing the pipeline
The pipeline takes about 36 hours for processing the en-
tire MEDLINE corpus and nearly 20 minutes for the
13,500 user comments from the health-related websites.
This includes the steps involving NER tasks such as POS
tagging, stemming, tokenization, acronym handling and
computing the entity association pairs.
A set of 12 drugs, which is the union of drugs that were
used by Wang et al. [1] and Leaman et al. [20] in their
study, was used for testing the pipeline (Table 1). The drugs
include: Bupropion, Carbamazepine, Olanzapine, Ciproflox-
acin, Trazodone, Ziprasidone, Aspirin, Ibuprofen, Warfarin,
Paroxetine, Rosiglitazone and Morphine. Bupropion is an
atypical anti-depressant and a smoking cessation agent
[37]. Carbamazepine, Olanzapine, Trazadone, Ziprasidone
and Paroxetine are different kinds of anti-psychotic or anti-
depressant drugs. Ciprofloxacin is an anti-biotic; Aspirin,
Ibuprofen and Morphine are different types of analgesic or
anti-inflammatory drugs. Rosiglitazone is an anti-diabetic
and Warfarin is an anticoagulant.
The label information for each of these 12 drugs was ob-
tained from the FDA website. These sections containing
the prescribing or label information vary from drug-to-
drug. Therefore depending on the information available
in the files obtained from the FDA website, the sections
used were the “Adverse Reactions”, “Warnings”, “Boxed
Warning”, “Precautions” and “Use in Specific Popula-
tions”. A comparative analysis of the label information for
each of the drugs was done with the AE pairs obtained.
The BCPNN algorithm was applied to the AE associa-
tions from the three sources - FAERS, health-related web-
sites and MEDLINE abstracts. The AE pairs with positive
variance values across these categories were considered as
potential signals for further analysis. PERL scripts were
used to create a tabular view of results for comparison
and analysis. Further, the results were grouped manually
for reporting.
Results
Table 2 shows the results of the pipeline for Bupropion, in
comparison with the results indicated by Wang et al. A
comparative analysis of the results is reported for Bupro-
pion as a representative out of the 12 drugs used for test-
ing the pipeline. Wang et al. depict their qualitative
evaluation of the results under four classes of associations
into which the experts categorize the results obtained
from their methods. The results for the other drugs is
available as supplementary file (Additional file 1).
 Reference standard, which is constructed by the







Figure 1 The pipeline depicting the sequential steps to identify the AE pairs from the various sources.
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 Remote Indication Association
 Unknown Associations
We have used these categories of results for comparative
purposes. Bupropion, however, according to the Wang
et al. study does not have any Unknown Associations.Table 3 shows the result of the comparative analysis of
the pipeline results with the label information for Bupro-
pion. Each row of the table shows different AEs grouped
together, separated by a semicolon (;). The known AEs
from label information for Bupropion, such as “nausea”,
“dizziness” and “suicidal behavior” were identified. AEs
such as “binge eating disorder”, which might lead to
Table 1 Details of the drugs, as indicated by Wang et al. and Leaman et al., used in the current work
No Drug name Drug type Synonyms Indications Known AEs











difficulty, drugged state, fatigue,
constipation sleeplessness, seizure,









Biston, Calepsin, Carbatrol, Equetro,
Sirtal, Stazepine, Telesmin, EPITAB XR,
Teril, Timonil, Trimonil, Epimaz,
Carbama, Carbamaze, Carzine, Mazetol,
Tegrita, Tegrital, Karbapin, Hermolepsin,
Degranol, Tegretal, Mannomustine,
Mannitlost, Decranol, Mannitol mustard




Zyprexa, Zydis, Relprevv, Zyprexa
Relprevv
Schizophrenia, bipolar disorder Weight gain, alteration in lipids,
somnolence or fatigue, increased
cholesterol, diabetes
4 Ciprofloxacin Antibiotic Ciprofloxacin hydrochloride, Ciprinol,
Cipro, Baycip, Ciloxan, Ciflox, Cipro XR,
Cipro XL, Ciproxin, Prociflor, Proquin,
Proquin XR, Ciprex, Cetraxal, Axcin






Trazodon neuraxpharm, Molipaxin, Apo
trazodone, Trittico, Deprax, Novo
trazodone, Pms-trazodone, Nu-
trazodone, Nu trazodone, Desyrel, Olep-
tro, Beneficat, Desirel, Trazorel, Trialodine,
Mesyrel
Depression Somnolence or fatigue, headache,










Zorprin, Magnecyl, Acetylsalicylic acid,
Polopirin, Solupsan, Endosprin,
Polopiryna, Acetysal, Easprin, Ecotrin,
Aloxiprimum, Colfarit, Dispril, Solprin,
Micristin, Acylpyrin, Empirin, Bufferin,
Fasprin, Genacote, Halfprin
Pain, fever, reduce blood
clotting
Nausea, vomiting, ulcers, bleeding,
stomach pain or upset
8 Ibuprofen Analgesic/anti-
inflammatory
Salprofen, Trauma-dolgit gel, Trauma
dolgit gel, Rufen, Nuprin, Brufen,
Motrin, Ibumetin, Nurofen, Advil
Pain of rheumatoid arthritis,
osteoarthritis, menstrual











Seroxat, Paroxetine maleate, Paxil,
Aropax, Paroxetine acetate, Paroxetine




disorder, social anxiety disorder
Pain chest, drowsiness, orthostasis,
dyspnea, agitation, dizziness,
feeling suicidal
11 Rosiglitazone Antidiabetic Avandia, Rosiglitazone maleate, Diabetes Headache, chest pain, left atrial
hypertrophy, shortness of breath
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Table 1 Details of the drugs, as indicated by Wang et al. and Leaman et al., used in the current work (Continued)
12 Morphine Analgesic/anti-
inflammatory
Morphia, Oramorph SR, Duramorph,
Morphine chloride, Morphine sulfate,
Ms contin, Mir, Morin, Nepenthe, Mirs,
Micro-rna, Avinza, Kadian, Morphine ir,
Msir, Roxanol, Infumorph, Kapabloc,
Kapanol, Loceptin, Longphine, Malfin,
Maxidon, Meconium, Meslon,
Micro-morphine, Mogetic, Morapid,
Moraxen, Morcap, Moretal, Morfenil,
Morficontin, Morfin, Morfin meda,
Morfina, Morph, Morphanton, Morphex,
Morphgesic, Morphin, Morphini,
Morphinum, Morphiphar, Morphitec,
Morphium, Morstel, Mos, Moscontin,
Morstel, Mortificontin, Ms direct, Ms
long, Ms mono, Mst continus, Mst
unicontinus, Mundidol, Mxl, Neocalmans,
Noceptin, Oblioser, Oglos, Oms
concentrate Onkomorphin, Opitard,
Opsalvina, Oramorph, Ordine, Relimal,
Relipain, Repriadol, Rescudose, Sevredol,
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Also, unique AEs were reported for Bupropion, such as
“airway obstruction” and “breathlessness” in blogs, which
might result from known reactions such as “angioedema”.
One of the common trends noticed from these top
scoring events for the drugs used in this study as listed
in Table 4 is that in FAERS only the side effects or ad-
verse events were high scoring, while in the other two
sources some of the drug indications came up with a
high score. This is possible because in these unstruc-
tured sources, the patients could have mentioned the
reason for which the drug was administered or the early
signs and symptoms they noticed for which the drug
was prescribed.
Table 5 contains the top scoring adverse events across
the three sources for anti-depressant/anti-psychotic class
of drugs used in this study, which are prescribed for
neurological problems. There are a few noticeable re-
sults. For example, side effects such as cardiac disorders,
sleep disorders and priapism come up as high scoring
ones for an anti-depressant drug such as Trazadone.
Heart diseases also show up as high-scoring adverse
events for an anti-diabetic drug such as Rosiglitazone.
The results also show the association pairs Warfarin-
INR, Warfarin-BCR and Warfarin-Vitamin K among the
top scoring ones. Warfarin is an anti-coagulant commonly
used to prevent thrombosis and thromboembolism, the for-
mation of blood clots in the blood vessels and their migra-
tion elsewhere in the body, respectively. International
Normalized Ratio (INR) is a measure of a pathway of co-
agulation while BCR is the test for blood clotting response.
And, it is known that vitamin K is required for blood co-
agulation. Hence, the addition of MedDRA terms to theentity dictionary has contributed to Vitamin K showing up
as a top scoring result, even though it is not really a dis-
ease or symptom term or even an adverse event by itself.
The supplementary material contains the comparative
analysis of the pipeline results with the label information
for some of the drugs, along with the top scoring results
for the remaining drugs.
Discussion
A semi-automated PV pipeline was built in this study,
which includes an in-house application TPX. This pipeline
serves as a framework for normalization of input from
multiple sources and a semi-automated extraction of po-
tential AE pairs from them. The pipeline was tested with a
set of 12 drugs drawn from Wang et al. [1] and Leaman
et al. [20]. An analysis of the top scoring results for each
of these drugs shows that the three sources individually
contribute to the identification of drug-adverse event pairs
and that no single source caters completely to the poten-
tial drug-adverse event pairs all by itself. However, two
patterns emerge from the comparative analysis of the
BCPNN results of blogs with the label and FAERS results:
1. Some of the AEs reported in blogs were more
specific when compared to the label information.
2. Some unique AEs were found in the health-related
websites
The data sources used in this study are the validated
set of AE pairs from FAERS, medical literature from
MEDLINE and blog content health-related websites
PatientsLikeMe, Mediguard and DailyStrength. These
selected sources are only examples for each type of data
Table 2 A comparison of the results from the pipeline with those from the study of Wang et. al
BUPROPION
(Treatment indications: depression and smoking cessation aid)
Reference standard Known AEs Indication associations Remote indication
associations
Wang et. al Constipation, dizziness,
drowsiness, dry mouth,
headache, pruritus, increased













Motor retardation, fall, jumpy,
stiffness, early satiety,
extrapyramidal sign, energy
increased, malingerer, rale, urge
incontinence, bulimia, yellow
sputum, emaciation

















sleep deprivation, sleep initiation
and maintenance disorders,
sleep disorders, sleep apnea
syndrome, seizures, tinnitus,
pruritus, depression, major

















appetite, nausea, nausea and
vomiting, vomiting, restless legs







sleep arousal disorders, loss of
weight, weight increase,
overweight, weight, body









voiding difficulty, fatigue, mental
fatigue, fatigue syndrome
chronic, constipation, sleep





sleep arousal disorders, seizures,




seizures, seizures febrile, tinnitus,
pruritus, suicidal behavior,
suicidal ideation, drug toxicity,
drug-specific antibodies, drug
screen, abnormalities drug-







resistance, fixed drug eruption,
extensively drug-resistant
tuberculosis, drug eruptions,













seizures, epilepsy partial motor,
motor fluctuations, rhinitis
vasomotor, oculomotor nerve
diseases, fall, fear of falling,
extrapyramidal symptoms, moist





weight loss, loss of weight
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Table 2 A comparison of the results from the pipeline with those from the study of Wang et. al (Continued)
AERS Constipation, dizziness, dizziness




application site pruritus, ear
pruritus, vulvovaginal pruritus,
anal pruritus, eye pruritus,
infusion site pruritus, injection











sleep terror, irregular sleep
phase, sleep phase rhythm
disturbance, abnormal sleep-
related event, poor quality
sleep, weight decreased, weight
increased, overweight, weight
abnormal, weight loss poor,
atonic seizures, complex partial





abnormal sensation in eye,
burning sensation, fatigue,
constipation, sleep disorder,
sleep apnoea syndrome, rapid
eye movements sleep abnormal,
sleep terror, irregular sleep
phase, sleep phase rhythm
disturbance, abnormal sleep-
related event, poor quality sleep,
atonic seizures, complex partial
seizures, partial seizures, tinnitus,
pruritus, pruritus generalised,
pruritus genital, instillation site
pruritus, application site pruritus,
ear pruritus, vulvovaginal pruritus,
anal pruritus, eye pruritus, infusion
site pruritus, injection site pruritus,
suicidal behaviour, depression
suicidal, suicide attempt, suicidal
ideation, drug intolerance, drug
hypersensitivity, drug interaction,
intentional drug misuse, drug
withdrawal syndrome
Suicidal behaviour, depression


















fear of falling, musculoskeletal
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http://www.biomedcentral.com/1472-6947/14/13and by no means implies that these are the authorata-
tive sources for such data. There are other medical
literature sources (PMC) or social media (other health-
related websites) that could be of equal, if not more,
value.
The blogs in health-related websites are not grammat-
ically correct by nature. The language used can be very
complex with varying writing styles. The format, struc-
ture, and style continuously evolve over time. Moreover,
these blogs may not completely abide by the guidelines
for AE reporting such as fulfilling the basic PRED cri-
teria; which may not be entirely reliable. Also, they may
not be validated by a trained investigator, the seriousness
of the AE may not be explicitly specified, there might
occur a considerable time-delay before being mentioned
in the blog, they could be reported by a third-party or
may have occurred concomitantly. However, the main
topics of discussion in blogs of the health-related web-
sites are medications, physiology and disorders. It has
been observed that patients are concerned by medica-
tion, while physicians rather focus on illnesses [38].
Some components of the pipeline involve manual
tasks. The pre-processing stage that involves data prep-
aration contains a few manual steps. The user comments
from the health-related websites were obtained using the
Web-Harvest tool. This tool requires the scripts for data
extraction to be written in xml. The user comments,thus obtained for each drug, were further broken down
into individual records using a Perl script. PV-TPX is
run on these individual records, each considered as a
document. The post-processing stage, after the identifi-
cation of drug and symptom or disease pairs, also in-
volves some manual tasks such as preparing this data in
a matrix form, which is the required input format for
running the BCPNN algorithm. Also, the results ob-
tained from the BCPNN algorithm were sorted based on
their IC variance values and were then manually ana-
lyzed to identify the potential drug-adverse event pairs,
for each drug across each of the sources.
Mining user comments from health-related websites
helps avoid the time-consuming process of getting formal
ethical approval for involving patients in direct primary re-
search [39]. However, there is the issue of ethics as a con-
cern while using data from such websites. In fact, a
number of ethical considerations concerning the reporting
of data obtained from the Internet have already been dis-
cussed and reported at great length by others [40-42].
There is however a growing consensus among researchers
that if Internet data is freely and publicly accessible, then
it can be used for considered research without prior
approval. Based on this, data taken from the Internet have
in fact been widely used already [39]. Most often users
post to health-related websites with their user-names or
other handles without disclosing any personal information.
Table 3 Burproion: comparative analysis of the label information from FDA and the results of BCPNN on blogs, AERS
and MEDLINE data
BUPROPION
Label Blogs AERS MEDLINE
Angioedema Airway obstruction; hoarseness Angioedema; Angioedema
Myalgia Fibromyalgia Fibromyalgia; myalgia –




Muscle atrophy; muscle spasm; muscle strain; muscle
twitching; musculoskeletal discomfort; musculoskeletal
stiffness
–
Polyuria; dysuria; glucosuria Proteinuria; hematuria Nocturia; pollakiuria –
Liver damage Liver failure – –
Dry mouth; dry skin; dry eye; Dehydration; dry mouth; dry
eye syndrome;
Dry mouth; dry skin Dry mouth;
dry eye
Constipation; and headache - - -
Chest pain Breast neoplasms; neoplasms; Breast cancer female; breast pain; drug exposure via
breast milk; neoplasm; non-cardiac chest pain
Lung
neoplasms
Neck pain Back pain; intervetebral disc
displacement; chronic pain;
Neck pain
Back pain; neck pain; inter-vertebral disc injury;
inter-vertebral disc protrusion
–
Dream abnormality Bad dreams Abnormal dreams –
– Constriction, pathologic – –




– Kidney diseases – –
Binge eating Eating disorders; diabetes
mellitus, type 2
Diabetes mellitus inadequate control; type 2 diabetes




Urinary frequency, urinary incontinence,
urinary urgency, urinary retention, urine
abnormality
– Urine abnormality, metanephrine urine increased –
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such as name, age and other demographics are not used
or reported as part of the results of the study, the ethical
issues such as privacy should not pose a significant
concern.
Spam and malicious posts could affect to the content of
such health-related websites and hence bias the results of
any such analysis. However, unlike most regular blogs and
bulletin boards, these health-related websites have moder-
ators looking at content posted by users and removing
such content, when encountered. For example, Daily-
Strength has a policy against both spammers and trolls.
It defines spammers and trolls as follows: a spammer is
someone who posts prolifically on dailystrength and on
the comment systems in order to promote links or prod-
ucts, often of a commercial interest while a troll is some-
one who posts with the intent to rile up communities,
provokes others into arguments or attacks, steers discus-
sions off-topic and prevents them from being helpful, or
disrupts and pollutes a support group with negativity.
There has been an increase in the number of commercial
websites developed aiming to aggregate user commentsfrom various health-related websites to obtain potential AE
pairs. Treato is an example of one such website, which
automatically collects the large amount of patient-written
health experiences from health-related websites and uses
advanced NLP to extract relevant information and create a
comprehensive picture of what people say about their
medications and conditions [43]. The website displays all
the AE pairs as part of the results. An important aspect of
our pipeline, when compared to Treato, is the grouping of
AEs based on different criteria, such as synonyms or vari-
ants of other AEs. In the absence of an ontology for
normalization, this step is critical for the identification and
comparative analysis of AEs in the final results. Lack of
such grouping results in presenting an incorrect picture.
Treato, for example, displays the results for individual AEs
separately with no grouping For example, “drowsy” and
“sleepy” are reported as two separate AEs for Bupropion in
Treato, thus displaying a larger number of AEs, even
though they are inter-related.
The statistical algorithm BCPNN, which was applied
in this work, generates association rules based on fre-
quency. Many such quantitative methods have been used









1 Aspirin FLUSHING COLITIS 3.0453446021 HEMORRHAGE 2.2974781367 ANTIPLATELET
THERAPY
6.4498501796
COLLAGENOUS 2.967777029 ASTHMA 1.7849414476 ASTHMA, ASPIRIN-
INDUCED
6.2465967694
GASTROINTESTINAL ULCER 2.8231226105 ULCER 1.6889750542 PLATELET
AGGREGATION
4.9990559736
2 Bupropion PSORIASIS 3.0858333183 SMOKING 2.8487222833 TOBACCO USE
DISORDER
6.7616174378




CRYING 2.9716117286 WEIGHT LOSS 1.9125982688 DEPRESSIVE
DISORDER, MAJOR
5.0765060025
3 Carbamazepine ANTICONVULSANT DRUG LEVEL
INCREASED
3.8394557589 SEIZURES 2.1831882505 TRIGEMINAL
NEURALGIA
5.7366534252
DRUG RASH WITH EOSINOPHILIA
AND SYSTEMIC SYMPTOMS
3.5911285749 EXANTHEMA 1.8627395675 EPILEPSIES, PARTIAL 5.5948458460
EPILEPSY 3.0298491782 LYMPHOMA 1.4381580775 STEVENS-JOHNSON
SYNDROME
5.3815350109
4 Ciprofloxacin TENDON RUPTURE 4.1146259253 UTI 2.8856797854 MBC 4.6062736746
TENDONITIS 4.0060829925 DIVERTICULITIS 2.2799989819 CROSS RESISTANCE 4.4062217226
TENDON PAIN 3.6892637795 ACNE VULGARIS 1.7510888515 DYSENTERY,
BACILLARY
4.3850295544
5 Ibuprofen KOUNIS SYNDROME 2.9815043448 PAIN 2.3836377566 DUCTUS ARTERIOSUS,
PATENT
4.8635855143
TOXIC EPIDERMAL NECROLYSIS 2.8890346654 OSTEOARTHRITIS 1.9773610941 ACUTE PAIN 4.4671583670
OSTEOARTHRITIS 2.8760959875 STOMACH ULCER 1.6554329992 OSTEOARTHRITIS 3.5868790708
6 Morphine ACUTE CHEST SYNDROME 3.9896519753 HASHIMOTO DISEASE 0.9969507103 POSTOPERATIVE
ANALGESIA
5.9041759822
ACCIDENTAL DEATH 3.5380803319 BREATHLESSNESS 0.9969507103 OPIATES 5.8450420720
CARDIO-RESPIRATORY ARREST 3.2009993755 VIOLENT 0.995428479 OPIOID-RELATED
DISORDERS
5.4082024508
7 Olanzapine HOSPITALISATION 3.6824877733 DIABETES MELLITUS 1.96163018 SCHIZOPHRENIA 5.7849079521
LEUKOPENIA 3.2803137933 OVERWEIGHT 1.8868082131 BIPOLAR DISORDER 5.7118297960
METABOLIC SYNDROME 3.1617168832 FEELING COLD 1.4527063824 PSYCHOMOTOR
AGITATION
5.6353982109
8 Paroxetine CONGENITAL ANOMALY 3.1300167523 ANXIETY DISORDERS 1.5594343083 HAM 5.6353454077
ATRIAL SEPTAL DEFECT 3.1224780702 PHOBIC DISORDERS 1.5388697964 DEPRESSIVE
DISORDER, MAJOR
5.5424233484
CARDIAC MURMUR 2.9842039722 HOT FLASHES 1.4317963274 PANIC DISORDER 5.3198511794
9 Rosiglitazone HEART INJURY 1.5296202559 HEART DISEASES 1.9460752101 DIABETES MELLITUS,
TYPE 2
5.5082168188
CARDIOVASCULAR DISORDER 1.5209213985 DIABETES MELLITUS 1.6536311321 INSULIN RESISTANCE 5.4173083948
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Table 4 Top scoring adverse events for each of the drugs used in this study (Continued)




SUICIDAL IDEATION 2.3695413431 CONDYLOMATA
ACUMINATA
1.3983875588 OVERDOSE 4.5116173724





4.2516503259 VITAMIN K 6.1945919883
CALCIPHYLAXIS 2.8692951662 HEMORRHAGE 2.8983756918 BCR (BLOOD
CLOTTING RESPONSE)
5.8376604098
BLUE TOE SYNDROME 2.8692951662 STROKE 2.5276002364 THROMBOEMBOLISM 5.7963964427
12 Ziprasidone TARDIVE DYSKINESIA 4.2677078217 VOMITING 1.9460228686 SCHIZOPHRENIA 5.7401521972
DYSTONIA 4.0558212672 TREMOR 1.831079029 QT INTERVAL 5.6217692996
EXTRAPYRAMIDAL DISORDER 3.7617945087 PSYCHOTIC
DISORDERS
1.6030569698 BIPOLAR DISORDER 5.6013438249
The scores here are the variance values obtained from running the BCPNN algorithm on the drug-AE pairs.
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For example, the FDA uses Multi-item Gamma Poisson
Shrinker (MGPS) to detect potential AE signals in its Med-
Watch program [44]. The UK Medicines Control Agency
adopts Proportional Reporting Ratio (PRR) and Chi-square
statistic to identify AE signals [45]. The Netherlands Phar-
macovigilance Centre Lareb uses the Reporting Odds Ratio
[46] and the Uppsala Monitoring Center employs Bayesian
Confidence Propagation Neural Network (BCPNN) as its
signal detection method on the WHO database [47]. While
all these different methods have the ability to detect po-
tential AE pairs, BCPNN is seen to have the best perform-
ance when compared to PRR and MGPS [48]. Hence, we
decided to implement and incorporate BCPNN in our
pipeline.
Of course, there are some drawbacks of using BCPNN
or some statistical algorithms in general. The IC value in
BCPNN does not give any information about the causal-
ity of an AE combination. The positive quantitative asso-
ciation between the drug and the AE is likely to be high,
although clinical assessment remains essential. Typically,
rare associations are not frequently reported. However,
BCPNN works sufficiently well as the data augmentation
from blogs and MEDLINE abstracts add up for these as-
sociations, which were traditionally viewed only from
FAERS as rare ones. Hence, even to detect infrequent
signals from multiple sources, we propose that our pipe-
line can be used.
The pipeline is not a fully-automated one. Some compo-
nents of the pipeline involve manual tasks. The pre-
processing stage that involves data preparation contains a
few manual steps. The user comments from the health-
related websites were obtained using the Web-Harvest
tool. This tool requires the scripts for data extraction to be
written in xml. The user comments, thus obtained for each
drug, were further broken down into individual recordsusing a Perl script. PV-TPX is run on these individual
records, each considered as a document. The post-
processing stage, after the identification of drug and
symptom or disease pairs, also involves some manual
tasks such as preparing this data in a matrix form,
which is the required input format for running the
BCPNN algorithm. Also, the results obtained from the
BCPNN algorithm were sorted based on their IC vari-
ance values and were then manually analyzed to identify
the potential drug-adverse event pairs, for each drug
across each of the sources.
Conclusion
We have built a semi-automated pipeline to extract the AE
pairs from adverse event databases, enhanced by potential
drug-adverse event pairs mined from non-traditional
sources such as text from MEDLINE abstracts and user-
comments from health-related websites. Testing the pipe-
line shows that although these non-traditional sources by
themselves cannot be alternatives for AE detection, mining
such sources helps substantiate the adverse event data-
bases. They not only contain the known AEs, but also sug-
gest unknown and unreported AEs for drugs, which can
be analyzed further. While pharmaceutical companies may
not want to incorporate these kinds of tools in their PV
programs, the pipeline could prove to be useful for better
PV by regulatory agencies, albeit with greater validations
in place.
Future work
The amount of automation in the pipeline can be in-
creased, thus extending the semi-automated pipeline
used for the current study. However, manual interven-
tion will always be required. A weighting scheme for
assigning more weight to associations from FAERS over
associations from unstructured text can be designed and
Table 5 Top scoring adverse events for a class of drugs in this study, which are anti-depressant/ antipsychotic drugs prescribed for neurological problems,
across the three different sources







ZIPRASIDONE TARDIVE DYSKINESIA 4.2677078217 BUPROPION SMOKING 2.8487222833 BUPROPION TOBACCO USE DISORDER 6.761617438
ZIPRASIDONE DYSTONIA 4.0558212672 CARBAMAZEPINE SEIZURES 2.1831882505 OLANZAPINE SCHIZOPHRENIA 5.784907952
CARBAMAZEPINE ANTICONVULSANT LEVEL DRUG INCREASED 3.8394557589 BUPROPION INTERACTION 2.0278154524 ZIPRASIDONE SCHIZOPHRENIA 5.740152197
ZIPRASIDONE EXTRAPYRAMIDAL DISORDER 3.7617945087 TRAZODONE BACK PAIN 2.0113279316 CARBAMAZEPINE TRIGEMINAL NEURALGIA 5.736653425
ZIPRASIDONE AKATHISIA 3.6922456683 OLANZAPINE DIABETES
MELLITUS
1.96163018 OLANZAPINE BIPOLAR DISORDER 5.711829796
OLANZAPINE HOSPITALISATION 3.6824877733 ZIPRASIDONE VOMITING 1.9460228686 OLANZAPINE PSYCHOMOTOR AGITATION 5.635398211
CARBAMAZEPINE DRUG RASH WITH EOSINOPHILIA AND
SYSTEMIC SYMPTOMS
3.5911285749 BUPROPION WEIGHT LOSS 1.9125982688 PAROXETINE HAM 5.635345408
ZIPRASIDONE BRUXISM 3.3493728888 OLANZAPINE OVERWEIGHT 1.8868082131 ZIPRASIDONE QT INTERVAL 5.621769300
OLANZAPINE LEUKOPENIA 3.2803137933 CARBAMAZEPINE EXANTHEMA 1.8627395675 BUPROPION SUBSTANCE WITHDRAWAL
SYNDROME
5.616013843
CARBAMAZEPINE ANTICONVULSANT DRUG LEVEL ABOVE
THERAPEUTIC
3.2657628102 ZIPRASIDONE TREMOR 1.831079029 ZIPRASIDONE BIPOLAR DISORDER 5.601343825
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ported. Another challenge is to successfully differentiate
between indications, symptoms of these indications, and
known contraindications. Also, a hierarchical representa-
tion or an ontology of the AEs can be built, in order to
group them for further analysis.
Additional file
Additional file 1: Pipeline results for some of the drugs used in the
study, as well as top 10 results for each of the drugs.
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